Leadership

Executive Team & Board of Directors

Neuronetics is led by visionaries in the fields of medical technology, life sciences, healthcare, business development, biomedicine, and pharmaceuticals. Each of these individuals brings a unique skill set to our leadership that gives us the opportunity to do better, and be better, every day. We drive learning and growth. We create positive change. We remain inspired by transforming lives.

“We are fortunate to have these leaders providing strategic guidance and championing our mission day in and day out.”

—Keith Sullivan, President & CEO

Executive Team

Keith Sullivan

Keith Sullivan

President & CEO

Keith Sullivan

Keith Sullivan

President & CEO

Mr. Sullivan most recently served as Chief Commercial Officer and President (North America) of ZELTIQ Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform under the Coolsculpting® brand, from January 2016 until the acquisition of ZELTIQ by Allergan, Inc. in April 2017. Mr. Sullivan previously served as Senior Vice President and Chief Commercial Officer of ZELTIQ from November 2014 until January 2016 and as Senior Vice President of Worldwide Sales and Marketing from July 2013 through October 2014.
Mr. Sullivan, who has more than 30 years of senior sales leadership experience in the medical device industry, has previously held leadership positions with Medicis Pharmaceuticals, Reliant Technologies, Medtronic, Vision Quest Laser Center and Coherent Medical.
Mr. Sullivan received a Bachelor of Business Administration from the College of William and Mary and is a clinical professor in the Mason School of Business at William and Mary. Mr. Sullivan currently serves on the Boards of Directors of Sientra, Inc. and Venus Concept.

Cory Anderson

Cory Anderson

VP Clinical Affairs & Interim VP R&D

Cory Anderson

Cory Anderson

VP Clinical Affairs & Interim VP R&D

Cory Anderson joins Neuronetics with over 20 years of medical technology experience, along with deep executive leadership within medical device startup companies.

Most recently, Mr. Anderson served as Vice President, Business Development and Marketing (Corporate Officer) at Sebacia. During his time at Sebacia, he led phase IV clinical trials in five countries and strategically guided the company’s R&D pipeline. Prior to Sebacia, he was VP Business Development at The Innovation Factory (TIF, the incubator where Neuronetics started) and a Principal at Accuitive Medical Ventures (AMV, venture investor in Neuronetics). During his time at TIF and AMV, Mr. Anderson managed operations of two portfolio companies in the ophthalmic space, evaluated new business/investment opportunities, and supported investments in the portfolio of companies.

Prior to his time at TIF and AMV, Mr. Anderson held positions of increasing responsibility within Product Development and Marketing at Novoste Corporation where he developed products for interventional cardiology.

Mr. Anderson has been a board observer and investor in two successful exits of venture-backed companies: AqueSys (acquired by Allergan/AbbVie, NYSE: ABBV) and MyoScience (acquired by Pacira BioSciences, NASDAQ: PCRX).

Mr. Anderson holds Bachelor’s and Master’s degrees in Biomedical Engineering from Tulane University, and an MBA from Emory University. Mr. Anderson is an inventor on seven issued US patents and an author of two peer-reviewed papers and one book chapter.

Todd Cushman

Todd Cushman

VP Business Development

Todd Cushman

Todd Cushman

VP Business Development

Prior to joining Neuronetics, Mr. Cushman was a founding member of Bioness, Inc., a medical technology company specializing in neuro rehabilitation and implantable products for pain management. At Bioness, he held various commercial and operational roles from 2004 – 2012, and served as President and CEO from 2013 until the company was acquired by Bioventus, Inc., in March of 2021. During his tenure at Bioness, Mr. Cushman work closely with the Chairman of the Board, renowned medical entrepreneur Alfred Mann, to develop Bioness and acquire, sell and license medical device IP, technologies and companies in the Mann Group. He brings with him extensive experience in executive leadership, product development, global operations, mergers and acquisitions.

Mr. Cushman began his career in medical devices at American Hospital Supply Corporation (now Baxter, Inc.) in sales and marketing. In 1984, he founded Acumed, Inc., a medical manufacturing and distribution company which was acquired by Medtronic, Inc. in 1999. From 1999 – 2004, Mr. Cushman served as Group Director for Medtronic’s Neurosurgical, Spinal Products and Image-guided Surgery Divisions.

Mr. Cushman has a BA from Brown University and an MBA from the Marshall School of Business at the University of Southern California. Mr. Cushman serves on the Boards of Directors for Voiceitt and the Alfred Mann Institute at the Technion – Israel Institute of Technology.

Steve Furlong

Steve Furlong

SVP, CFO & Treasurer

Steve Furlong

Steve Furlong

SVP, CFO & Treasurer

Steve Furlong is Neuronetics Senior VP, Chief Financial Officer, and Treasurer, and has been with the company since July 2019. Prior to joining the company, Mr. Furlong worked at Metabolon, a private life science company in metabolomics, a phenotyping technology for advancing biomarker discovery, diagnostic testing and precision medicine, from November 2017 to July 2019, where he most recently served as Senior Vice President of Finance and Corporate Secretary.
Prior to joining Metabolon, Mr. Furlong was Vice President Finance at Verscend Technologies from February 2017 to June 2017. From April 2015 to September 2016, Mr. Furlong served as Chief Financial Officer of Rapid Micro Biosystems, which manufactures and distributes products for detection of microbial contamination. Before joining Rapid Micro Biosystems, Mr. Furlong spent 14 years at Hologic, a publicly-traded medical technology company, where he held a number of roles of increasing responsibilities, most recently Senior Vice President, Finance and Sales Administration.
Prior to his experience at Hologic, Mr. Furlong held positions at Safety 1st, Stratus Computer Inc., and Raytheon Company. Mr. Furlong received his B.A. in Political Science from The Pennsylvania State University and his Master of Finance degree from Bentley University.

Rick Grubbs

Rick Grubbs

VP National Accounts

Rick Grubbs

Rick Grubbs

VP National Accounts

Rick Grubbs comes to Neuronetics with over 30 years of experience in sales and management. Prior to joining Neuronetics, his previous eight years were spent as Director of Sales with Allergan Aesthetics (formerly ZELTIQ), commercializing and growing the CoolSculpting brand.

Mr. Grubbs’ previous sales and management experience includes roles at Lumenis, Lutronic and Solta Medical, among other medical device and pharmaceutical companies. He earned his Bachelor of Arts degree in Communications from California State University, Fullerton.

Sara Grubbs

Sara Grubbs

VP of Sales

Sara Grubbs

Sara Grubbs

VP of Sales

Sara Grubbs brings 20 years of sales and management experience to Neuronetics and has spent the past 15 years successfully commercializing medical devices with a consumable component similar to NeuroStar®. She previously served in sales leadership and management roles with Revance Aesthetics, Allergan (formerly ZELTIQ), Ulthera, and Solta Medical as well as other medical device and pharmaceutical companies. Sara received her Bachelor of Science degree in Business and Entrepreneurship from the University of Southern California.

Andrew Macan

Andrew Macan

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

Andrew Macan

Andrew Macan

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

W. Andrew Macan has served as Neuronetics’ Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary since January 2020.

Prior to joining Neuronetics, Mr. Macan was Senior Vice President, General Counsel and Corporate Secretary of U.S. Silica Holdings, Inc., a Russell 2000 diversified minerals company, from October 2018 until January 2020. He served in roles of increasing responsibility with Axalta Coating Systems, LLC, from October 2013 until October 2018, most recently as General Counsel and Chief Compliance Officer, Americas, and The Chubb Corporation, from October 2003 until October 2013, including as Vice President, Corporate Counsel and Secretary for over 8 years.

Mr. Macan began his career in private practice at Ballard Spahr LLP and Dechert LLP. He earned a B.A. in Government from Franklin & Marshall College and his J.D. from Emory University School of Law with distinction and Order of the Coif.

Claire Sears

Claire Sears

Claire Sears

Claire Sears

Ms. Sears brings over 20 years of Sales and Marketing experience to Neuronetics. Her most recent previous experience was with Allergan Aesthetics, where she spent 8+ years working on SkinMedica and CoolSculpting in various roles that ran the gamut from product innovation to launch planning to in-market execution.

Prior to that, she spent several years as a Brand Marketer in Consumer-Packaged Goods, working on well-known brands such as Dove and Q-Tips, Lancôme Skincare, Listerine, Reach and Neosporin at Unilever, L’Oréal, and J&J Consumer. She also has experience on the agency side building digital campaigns and celebrity sponsorship programs for clients such as Charles Schwab. Her early career began with pharmaceutical sales and then transitioned to healthcare start-ups, working with physicians and advocacy groups to implement technology tools and electronic patient records.

Claire holds an MBA from Cornell and a Bachelor of Science in Biology from University of North Carolina.

Kara Thornton

Kara Thornton

VP, Human Resources

Kara Thornton

Kara Thornton

VP, Human Resources

Kara Thornton is Neuronetics VP of Human Resources, and has been with the company since July 2019.
Kara has over 20 years of Human Resources experiences in Life Sciences including Pharmaceutical, Biomedical, Consumer, Nutraceuticals and Medical Device. She has led both domestic and global Human Resources teams serving as a strategic HR business partner across all functions. Prior to joining Neuronetics, Kara was Head of Human Resources for the US branded pharmaceutical business at Sun Pharma where she supported the commercial and enabling businesses across 5 therapeutic areas.
Kara spent the large portion of her career at DSM, a global life and material sciences organization based in the Netherlands from 2008 – 2018. There, she spent 10 years in various roles of increasing levels of responsibilities across four business units including, Director, Human Resources in Pharmaceutical Products; Sr. Director Human Resources, Shared Services; Head of Human Resources, Biomedical; and Sr. Director, Human Resources, North America Region.
Prior to joining DSM, Kara held HR Business Partner positions at Johnson and Johnson, Bayer and Daiichi Sankyo. Kara holds a BA degree from Cabrini University in Communications and History.

Board of Directors

Rob Cascella

Rob Cascella

Rob Cascella

Rob Cascella

Robert A. Cascella joined the Neuronetics Board of Directors in April 2021. He has more than 30 years of experience in the healthcare industry in a range of senior management positions and has served on several boards.

Mr. Cascella joined Philips in 2015 and is currently a Special Advisor to the Company. Prior to this advisory role, he held the position of Executive Vice President and Strategic Business Development Leader at Royal Philips and was also a member of the company’s Executive Committee. Mr. Cascella has held several other leadership roles at Philips, including Chief Business Leader for the Precision Diagnosis Segment and Chief Business Leader of the Diagnosis and Treatment Segment. Over this period, Mr. Cascella was responsible for the turnaround of multiple lines of business and the completion of several strategic acquisitions.

Prior to Philips, Mr. Cascella spent ten years as President and later CEO of Hologic Inc., a global leader in women’s health. Over this period, Hologic grew from a $180 million capital equipment business to a $2.5 billion leader in women’s health.

Earlier in his career Mr. Cascella was a partner and executive committee member of CFG Capital, a boutique investment bank, where he represented the firm’s healthcare business. Over his career he has held various senior management positions ranging from CFO and VP Finance to President and COO for NeoVision, a breast ultrasound start-up company sold to US Surgical and Fischer Imaging.

Mr. Cascella has led or participated in over 15 acquisitions at an aggregate deal value of over $12 billion and has raised over $3 billion in debt and equity over his career. He holds a BA from Fairfield University. Currently he is on the Boards of Celestica (CLS: NYSE) a Canadian contract manufacturer and Metabolon a private company focused on the use of metabolomics for improved disease characterization.

John Bakewell

John Bakewell

John Bakewell

John Bakewell

John Bakewell joined the Neuronetics Board of Directors in May 2020. Mr. Bakewell has served in senior executive roles for nearly three decades, building and executing business strategies for growth companies across the medical device, specialty pharma, diagnostics and healthcare provider sectors, while also serving on public- and private-company boards.
Mr. Bakewell’s professional experience in the medical technology industry includes serving for nine years as Executive Vice President and Chief Financial Officer of Wright Medical Group, Inc., from its private equity-backed reorganization through the company’s initial public offering, multiple years of industry-leading growth and creation of its industry-leading lower extremities franchise; Vice President, Finance and Administration and CFO of Cyberonics Inc., during a crucial five year period as the company successfully developed, gained regulatory approval, launched and globally commercialized its breakthrough device-based therapy for epilepsy; Chief Financial Officer of Lantheus Holdings, Inc., a specialty pharmaceutical company providing radiopharmaceuticals and contrast agents for cardiovascular imaging; Executive Vice President and Chief Financial Officer of RegionalCare Hospital Partners, Inc., a private equity-sponsored hospital acquirer and operator; and Chief Financial Officer of Exact Sciences Corporation, a molecular diagnostics company commercializing a DNA screening test for the early detection of colon cancer. Altogether, Mr. Bakewell has served in executive capacities for 26 years with eight organizations (of which five were public companies), including experience beyond healthcare in the technology and industrial sectors. He began his career as a CPA with seven years, collectively, at KPMG and Ernst & Young serving growth-oriented businesses across multiple industries. Mr. Bakewell holds a Bachelor of Arts in Accounting from the University of Northern Iowa and is a certified public accountant (current status inactive).
Since 2017 Mr. Bakewell has served on the board of directors of Xtant Medical Holdings, Inc., a publicly-traded manufacturer and marketer of class-leading regenerative medicine products and medical devices, where he chairs the audit committee. He has previously served on several other public and private company boards, including Entellus Medical, Inc., then a NASDAQ-traded ENT-focused medical device company, serving as compensation committee chair and audit committee member until its acquisition; ev3, Inc., then a NASDAQ-traded, endovascular medical device company, serving as audit committee chair and nominating/corporate governance committee member until its acquisition; Corindus Vascular Robotics, Inc., then a NASDAQ-traded medical technology company and the global leader in robotic-assisted vascular interventions, serving as audit committee chair; and Keystone Dental, Inc., a private, dental implant medical device company, serving as audit committee chair until its merger.

Sheryl Conley

Sheryl Conley

Sheryl Conley

Sheryl Conley

Sheryl Conley brings more than 30 years of leadership experience in the medical device industry. Ms. Conley previously served as the Group President – Americas, Global Brand Management and Chief Marketing Officer at Zimmer Holdings, where she led the company’s largest and most profitable business segments. During her 25-year career at Zimmer, she held a number of escalating management roles across a variety of product segments and geographies, during which she provided key leadership in the development and commercial release of over 50 industry leading brands. She holds a Bachelor of Science in Biology and Chemistry and an MBA from Ball State University in Indiana. Ms. Conley is a member of the Audit committee.

Wilfred Jaeger

Wilfred Jaeger

Wilfred Jaeger

Wilfred Jaeger

Wilfred E. Jaeger, M.D. has served as a member of our Board of Directors since March 2005. Dr. Jaeger co-founded venture capital firms Three Arch Partners in 1993 and HealthInvest Equity Partners in 2013 and continues to serve as a Partner to both firms. Prior to co-founding Three Arch Partners, Dr. Jaeger was a general partner at Schroder Ventures. Dr. Jaeger also currently serves on the board of directors of Concert Pharmaceuticals, Inc., a public clinical stage biopharmaceutical company, Nevro Corporation, a public medical device company, as well as numerous private companies. Dr. Jaeger received a B.S. in Biology from the University of British Columbia, his M.D. from the University of British Columbia School of Medicine, and an M.B.A. from Stanford University.

Glenn Muir

Glenn Muir

Glenn Muir

Glenn Muir

Glenn P. Muir, a certified public accountant, has extensive experience in finance and financial reporting. Glenn was Hologic’s Chief Financial Officer from 1992 to May 2014 and its only Executive Vice President since 2000 with a broad range of operating responsibilities including the key architect in the formulation and implementation of the Company’s strategic initiatives.
While at Hologic for over 25 years Glenn was at the helm of the Company’s IPO in 1990 when it was a single-product single-disease niche medical product company and continuing to the leader it is today in women’s health. Hologic has grown and evolved to a provider of advanced technologies that make a difference in people’s lives with operations around the world, revenues of over $2.5 billion, an enterprise value exceeding $10 billion and over 6,000 employees.
Glenn has steered two companies through IPO’s (and numerous follow-on offerings), built world-class organizations, raised over $5 billion in debt and led the acquisition/integration of over twenty companies. His industry experience is specific to the healthcare industry and includes medical imaging, diagnostics and surgical solutions.
Currently a member of the Board of Directors and the Audit Committee Chair at Repligen Corporation (Nasdaq: RGEN – http://www.repligen.com/), ReWalk Robotics Ltd (Nasdaq: RWLK – http://rewalk.com/) and G1 Therapeutics, Inc. (http://www.g1therapeutics.com/). His past Board of Director experience also includes RainDance Technologies, Inc. from 2014 until its acquisition by Bio-Rad Laboratories in February 2017, Hologic, Inc. (Nasdaq: HOLX) from 2001 to 2013 and Vivid Technologies, Inc. (Nasdaq: VVID) from 1996 until the Company was sold to EG&G in 1999.
Glenn graduated from the University of Massachusetts in Amherst where he was Treasurer and Board Member of the UMass Student Federal Credit Union. He has two graduate degrees: a Master in Business Administration from Harvard University Graduate School of Business Administration (full-time) and a Master in Science in Taxation from Bentley College Graduate School of Business (part-time).
One of 2009 America’s Best CFOs as surveyed by Institutional Investor. Boston Business Journals 2011 CFO of the year.
Member of the American Institute of Certified Public Accountants and the Massachusetts Society of Certified Public Accountants.
Glenn lives in Lexington, Massachusetts with his wife and three children. With his family he enjoys the BVI, skiing, bridge and the Boy Scouts. His contact information is: glennmuir@outlook.com; Cell: (617) 633-2276.

Megan Rosengarten

Megan Rosengarten

Megan Rosengarten

Megan Rosengarten

Megan Rosengarten joined the Neuronetics Board of Directors in August 2021. Ms. Rosengarten is a proven leader known for commercializing new insights and opportunities, resulting in sustainable growth and iconic Brands.  She has broad experience across the medical device and consumer product industries, spanning over two decades of marketing and strategic leadership.

Ms. Rosengarten serves as President of Surgical Robotics at Medtronic, where she led the launch of a new robotics business and integration of an acquired medical training and AI start-up.

Prior to joining Medtronic, she served as the VP, Global Marketing for Hologic’s Breast and Skeletal Health Division where she served a key role in accelerating growth through product innovation and brand building. In addition, she has held a variety of roles in product management, marketing, and strategy at Covidien and Johnson & Johnson.

Ms. Rosengarten earned her M.B.A. from Kenan-Flagler Business School at UNC, with concentrations in marketing and international business, and her B.S. in Biological Anthropology and Anatomy from Duke University.

Bruce J. Shook

Bruce J. Shook

Bruce J. Shook

Bruce J. Shook

Bruce Shook is a medical device executive with more than 30 years of industry experience, including multiple early stage ventures focused on opportunities in cardiac surgery, cardiology, neurosurgery, psychiatry and vascular disease. He serves as Director, President and CEO for both Intact Vascular and Vesper Medical. Intact Vascular is a privately held medical technology company that develops and commercializes vascular scaffolding technology for the treatment of peripheral arterial disease. The company is currently marketing the Tack Endovascular System® in the U.S. and Europe. Vesper Medical was spun out of Intact Vascular in late 2016 and is developing a novel family of venous stents designed to treat deep venous disease.
Prior to Intact Vascular and Vesper Medical, Mr. Shook was co-founder, Director, President and CEO of Neuronetics, Inc., [NASDAQ: STIM] a publicly traded device company that markets a non-invasive brain stimulation technology for the treatment of depression.
Previously, Mr. Shook was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders, and President of Abiomed [NASDAQ: ABMD], where he obtained PMA approval for the first FDA-approved ventricular assist device. Mr. Shook also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.
Mr. Shook holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management, respectively. He earned a B.S. degree in Chemical Engineering from Penn State University. Mr. Shook currently serves on the Board of Directors at Neuronetics, Venarum Medical, the Penn State Research Foundation (Vice Chairman) and Life Sciences Pennsylvania (Medical Technology Committee Chairman). He previously served on the Board of Directors at Surgiquest, Respicardia and CoTherix.

Keith Sullivan

Keith Sullivan

President & CEO

Keith Sullivan

Keith Sullivan

President & CEO

Mr. Sullivan most recently served as Chief Commercial Officer and President (North America) of ZELTIQ Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform under the Coolsculpting® brand, from January 2016 until the acquisition of ZELTIQ by Allergan, Inc. in April 2017. Mr. Sullivan previously served as Senior Vice President and Chief Commercial Officer of ZELTIQ from November 2014 until January 2016 and as Senior Vice President of Worldwide Sales and Marketing from July 2013 through October 2014.
Mr. Sullivan, who has more than 30 years of senior sales leadership experience in the medical device industry, has previously held leadership positions with Medicis Pharmaceuticals, Reliant Technologies, Medtronic, Vision Quest Laser Center and Coherent Medical.
Mr. Sullivan received a Bachelor of Business Administration from the College of William and Mary and is a clinical professor in the Mason School of Business at William and Mary. Mr. Sullivan currently serves on the Boards of Directors of Sientra, Inc. and Venus Concept.

Learn More

For more information on what we do, how to join our team, or ways you can invest in our future, contact us today.

Contact Neuronetics